Maze Therapeutics posts smaller than expected Q1 loss

Maze Therapeutics

12/05/2026 21:09

Overview

US biopharmaceutical firm reported a Q1 net loss smaller than analyst expectations

Loss from operations was narrower than expected

Company recognized $20 mln license revenue from MZE001 milestone payment

Outlook

Maze expects to initiate a pivotal trial for MZE829 in moderate AMKD in H1 2027

Company plans to start two Phase 2 trials of MZE782 in PKU and CKD in 2026

Maze expects its cash runway to extend into 2029

Result Drivers

LICENSE REVENUE - Co recognized $20 mln in license revenue from a milestone payment under its agreement with Shionogi for MZE001

R&D EXPENSES - Higher R&D expenses driven by clinical trial costs for MZE829 in AMKD and start-up activities for MZE782 in PKU, as well as increased personnel-related costs

G&A EXPENSES - Increased general and administrative expenses due to higher personnel-related costs and professional services

Company press release: ID:nGNX9GGlQC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Beat
-$24.21 mln
-$27.48 mln (9 Analysts)
Q1 Income from Operations
Beat
-$26.55 mln
-$29.41 mln (9 Analysts)
Q1 Operating Expenses
$46.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Maze Therapeutics Inc is $56.50, about 121.4% above its May 11 closing price of $25.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)